Skip to main content
. 2022 Aug 12;12:976065. doi: 10.3389/fonc.2022.976065

Figure 2.

Figure 2

Advantages and limitations of different preclinical models for anticancer drug testing; (A) patient derived models, (B) non patient-derived animal models. GEMM, genetically engineered mouse model; GVHD, graft versus host disease; nGEMM, non-germinal genetically engineered mouse model; PDX, patient-derived xenograft; TEC, tumor explant culture; TME, tumor microenvironment; 2D, bi-dimensional; TSC, tumor slice culture.